Close Menu

The president and CEO of the Biotechnology Industry Organization, James Greenwood, tells the Boston Globe that the biotech companies will, for the most part, survive the recession. As a whole, he says, the industry has just started to make money, though because of the economy, there is a risk of some companies losing out. Greenwood also discusses generic biologics and data exclusivity as well as healthcare reform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.